Clinical Trials Logo

Leukemia clinical trials

View clinical trials related to Leukemia.

Filter by:

NCT ID: NCT05751044 Not yet recruiting - Clinical trials for Acute Lymphoblastic Leukemia

HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

HEM-iSMART B
Start date: October 1, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

HEM-iSMART is a master protocol which investigates multiple investigational medicinal products in children, adolescents and young adults (AYA) with relapsed/refractory (R/R) ALL and LBL. Sub-protocol B is a phase I/II trial evaluating the safety and efficacy of dasatinib + venetocolax in combination with dexamethasone + Cyclophosphamide and cytarabine in children and AYA with R/R ped ALL/LBL whose tumor present with alterations in the MAPK/SRC pathway.

NCT ID: NCT05749276 Not yet recruiting - Clinical trials for Adult Patients With Adverse Risk Acute Myeloblastic Leukemia

Escalation of Doses of Daratumumab in Combination With Chemotherapy (Idarubicin and Cytarabine) in Patients of 60 Years Old or More With Adverse Risk Acute Myeloblastic Leukemia (AML) (DARALAM)

DARALAM
Start date: May 2024
Phase: Phase 1
Study type: Interventional

To search for a Maximum Tolerated Dose (MTD) for the combination of daratumumab and induction chemotherapy with Idarubicin and cytarabine in patients with Acute Myeloblastic Leukemia (AML) of poor prognosis

NCT ID: NCT05745714 Not yet recruiting - Clinical trials for Acute Lymphoblastic Leukemia, in Relapse

HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

HEM-iSMART C
Start date: October 1, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

HEM-iSMART is a master protocol which investigates multiple investigational medicinal products in children, adolescents and young adults (AYA) with relapsed/refractory (R/R) ALL and LBL. Sub-protocol C is a phase I/II trial evaluating the safety and efficacy of ruxolitinib and venetoclax in combination with dexamethasone, cyclophosphamide and cytarabine in children and AYA with R/R ped ALL/LBL whose tumor present with alterations in the IL7R/JAK-STAT pathway.

NCT ID: NCT05745285 Not yet recruiting - Lymphoma Clinical Trials

Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care

Start date: July 1, 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to learn about the impact that the services and programs provided by the Leukemia and Lymphoma Society have among patients with blood cancer, such as access to care, quality of life, and financial burden.

NCT ID: NCT05739409 Not yet recruiting - Clinical trials for Acute Myelogenous Leukemia

LILRB4 STAR-T Cell Therapy for Monocytic Leukemia

Start date: February 2023
Phase: N/A
Study type: Interventional

This is a single-center,single-arm,open-label phase I clinical study to determine the safety and efficacy of LILRB4 STAR-T cells in Monocytic Leukemia subjects.

NCT ID: NCT05705570 Not yet recruiting - Clinical trials for Acute Lymphoblastic Leukemia, in Relapse

A Phase I Clinical Trial Using Genetically Engineered Autologous T Cells to Express Chimeric Antigen Receptor (CAR) for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies

CARTHIAE-1
Start date: March 1, 2023
Phase: Phase 1
Study type: Interventional

This is a phase l, single arm, prospective open, dose-escalation study in patients with relapsed or refractory CD19-positive B cell malignancies (ALL, NHL, CLL). The trial will include adult and pediatric patients. There will be three individual cohorts, defined by disease biology: pediatric ALL and aggressive pediatric NHL (Cohort 1), adult ALL (Cohort 2) and adult NHL/CLL (Cohort 3).

NCT ID: NCT05703204 Not yet recruiting - Clinical trials for Acute Myeloid Leukemia and Myelodysplastic Syndrome

A Study of QLF32101 in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome

Start date: February 1, 2023
Phase: Phase 1
Study type: Interventional

This study aimed to evaluate the safety,tolerability and preliminary efficacy of QLF32101 administered intravenously and subcutaneously in patients with R/R, AML.

NCT ID: NCT05667402 Not yet recruiting - Clinical trials for Allogeneic Hematopoietic Stem Cell Transplantation

Clinical Study of TBF Regimen in Allo-HSCT in Patients With CNS Leukemia

Start date: January 15, 2023
Phase: N/A
Study type: Interventional

Central nervous system (CNS) leukemia is a poor prognostic factor for allogeneic hematopoietic stem cell transplantation (allo-HSCT). Thiotepa can penetrate the blood-brain barrier and has immunosuppressive effects and similar effects to irradiation in allo-HSCT. This project aims to investigate whether the TBF regimen is superior to the traditional modified BuCY2 regimen to improve the long-term survival of the CNS leukemia patients.

NCT ID: NCT05664230 Not yet recruiting - Clinical trials for Lymphoblastic Leukemia

Efficacy of Osteopathic Treatment on the Side Effects of Curative Treatments of Lymphoblastic Leukemia in Pediatrics

Leucosteo
Start date: January 1, 2023
Phase:
Study type: Observational

During the curative treatment of cancer, pain often remains the dominant symptom affecting the physical and psychological state of the patient. Osteopathy is an exclusively manual practice whose goal is to compensate for mobility dysfunctions of the tissues of the human body. It can be used as a complementary treatment for cancer pain when pain medications are not enough. The aim of this study is to examine the effectiveness of osteopathy in reducing pain intensity and improving quality of life in patients treated for pediatric acute lymphoblastic leukemia.

NCT ID: NCT05662904 Not yet recruiting - Clinical trials for Relapsed/Refractory Acute Myeloid Leukemia (AML)

Genetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients With AML

GALAXY33
Start date: December 2023
Phase: Phase 1
Study type: Interventional

The study "GALAXY33" is an open-label, prospective, nonrandomized, one arm phase I clinical trial in which patients with relapsed AML after allogeneic hematopoietic stem cell transplantation will be transplanted with CD33-deleted CD34+ HSC derived from the initially matched family donor.